| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Assistant Surgery Eligibility Criteria | 2026-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Rozanolixizumab-noli (Rystiggo) | 2026-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Immune Globulin Therapy | 2026-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Gemcitabine | 2026-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Ustekinumab (Stelara) and Ustekinumab Biosimilars | 2026-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Intravesical Mitomycin (Zusduri) | 2026-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Nipocalimab-aahu (Imaavy) | 2026-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Esketamine (Spravato) | 2026-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Telisotuzumab vedotin-tllv (Emrelis) | 2026-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Carboplatin (Paraplatin) | 2026-01-01 |